- Details
- Pedro Barata discusses the work of his team on tivozanib, a selective androgenic therapy approved for patients with advanced renal cell carcinoma (RCC). Their research focused on non-clear cell RCC, a less common subset of RCC. The team re-examined a Phase II trial conducted several years ago, using tivozanib in a discontinuation trial. The trial enrolled over 270 patients, of whom over 45 had non...
|
- Details
- Pedro Barata discusses the TIVO-3 trial with Kathryn Beckermann. The trial assessed Tivozanib, a novel tyrosine kinase inhibitor (TKI), used in the treatment of refractory clear cell RCC patients. They explain that the primary endpoint of the trial was progression-free survival (PFS), but they also delve into the complexities of considering overall survival (OS) in global trials. This leads to a d...
|
- Details
- Pedro Barata interviews Mehmet Asim Bilen to discuss his recent research on neoadjuvant cabozantinib treatment in patients with renal cell carcinoma. Dr. Bilen elaborates on the study's design and rationale, stating that neoadjuvant therapy could potentially facilitate partial nephrectomy and understand the biology of the disease. The phase II study included 17 patients and reported a 30% response...
|
- Details
- Alicia Morgans hosts a discussion with William Hall and Rana McKay to discuss SAMURAI, the first cooperative group study that randomizes patients with kidney cancer between radiation and no radiation. Dr. Hall points out how radiation therapy has evolved over the past 15 years, offering high doses with millimeter accuracy that precisely targets malignancy while avoiding normal tissue. This evoluti...
|
- Details
- Pedro Barata hosts Kelly Fitzgerald known for her exceptional research in kidney cancer. They discuss Dr. Fitzgerald's paper in European Neurology, focusing on the progression-free survival of second line therapy for advanced clear cell in patients treated with Immuno-Oncology (IO) based approaches. Dr. Fitzgerald explains how they aimed to understand the therapeutic sequencing between ipilimumab...
|
- Details
- Pedro Barata and Brian Rini unpack the findings and implications of the KEYNOTE-426 trial. The trial assessed the efficacy of a pembrolizumab and axitinib regimen in advanced clear cell kidney cancer, contrasting it with the then-standard sunitinib monotherapy. The KEYNOTE-426 trial's success contributed to changing the standard of care in this field. It demonstrated superior response rates and pr...
|
- Details
- In this discussion, Pedro Barata interviews Dena Battle, who discusses a presentation centered around a survey conducted by Kidney Cancer Research Alliance (KCCure) to understand patient perspectives on kidney cancer treatment. The survey, which received over a thousand responses, specifically targeted metastatic patients and focused on their perceptions of successful treatment, therapy selection,...
|
- Details
- Pedro Barata interviews Nourhan El Ahmar to discuss the significant work conducted by El Ahmar's team. The work focused on a subgroup analysis of the HCRN GU16-260 platform study that investigated the use of nivolumab with ipilimumab as salvage therapy for patients with advanced renal cell carcinoma. El Ahmar delves into the specifics of the trial, explaining how their lab played a crucial role in...
|
- Details
- Pedro Barata converses with Benjamin Berger and Matthew Labriola about their research on the treatment of recurrent metastatic RCC after adjuvant immunotherapy. They delve into the history of trials for adjuvant therapy for RCC, specifically highlighting the major advancements, challenges, and the shift to immunotherapy. The experts discuss adjuvant pembrolizumab's approval, its effectiveness in h...
|
- Details
- Alicia Morgans interviews Toni Choueiri about the CONTACT-03 study, which explored the efficacy of re-challenging patients with renal cell carcinoma (RCC) using a PD-1 or PDL-1 inhibitor, post-tumor progression on prior PD-1 or PDL-1 inhibitor treatments. The study specifically used atezolizumab (a PDL-1 inhibitor) and cabozantinib (a tyrosine kinase inhibitor or TKI). The findings, unfortunately,...
|
